menu search

FATE / Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.68 per share a year ago. Read More
Posted: May 3 2023, 19:02
Author Name: Zacks Investment Research
Views: 092155

FATE News  

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

By GlobeNewsWire
October 25, 2023

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage more_horizontal

Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?

By Zacks Investment Research
September 7, 2023

Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? more_horizontal

Fate Therapeutics to Present at Upcoming September Investor Conferences

By GlobeNewsWire
August 31, 2023

Fate Therapeutics to Present at Upcoming September Investor Conferences

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage b more_horizontal

Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 8, 2023

Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to lo more_horizontal

Why Shares of Fate Therapeutics Soared This Week

By The Motley Fool
June 16, 2023

Why Shares of Fate Therapeutics Soared This Week

Fate Therapeutics is a clinical-stage biotech. The company focuses on cell-derived oncology and immunology therapies. more_horizontal

Fate Therapeutics: The Future Remains Cloudy

By Seeking Alpha
May 23, 2023

Fate Therapeutics: The Future Remains Cloudy

Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by more_horizontal

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 3, 2023

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to lo more_horizontal

Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
May 3, 2023

Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know

Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might dr more_horizontal


Search within

Pages Search Results: